Wendell David Associates Inc. decreased its position in shares of Eli Lilly and Co (NYSE:LLY) by 4.0% during the 4th quarter, HoldingsChannel reports. The fund owned 38,732 shares of the company’s stock after selling 1,600 shares during the period. Wendell David Associates Inc.’s holdings in Eli Lilly and were worth $3,271,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2.1% during the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after acquiring an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Eli Lilly and by 16.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after acquiring an additional 1,503,918 shares in the last quarter. Dodge & Cox raised its position in shares of Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Eli Lilly and by 91.1% during the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the last quarter. 76.35% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly and Co (LLY) traded up $0.59 on Tuesday, reaching $86.98. The company’s stock had a trading volume of 2,728,800 shares, compared to its average volume of 2,741,344. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $93,910.00, a P/E ratio of 41.42, a PEG ratio of 1.63 and a beta of 0.35. Eli Lilly and Co has a 52 week low of $74.00 and a 52 week high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 EPS. research analysts anticipate that Eli Lilly and Co will post 4.22 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.59%. Eli Lilly and’s payout ratio is 99.05%.

LLY has been the subject of several research reports. BMO Capital Markets restated a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday. Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $86.98 to $95.00 in a research report on Tuesday. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $92.75.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 251,088 shares of company stock valued at $22,041,236 over the last quarter. 0.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Co (LLY) Shares Sold by Wendell David Associates Inc.” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/16/eli-lilly-and-co-lly-shares-sold-by-wendell-david-associates-inc.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.